ISRCTN25688299 https://doi.org/10.1186/ISRCTN25688299

Effect of Stem-Kine Food Supplement on Circulating Stem Cells

Submission date	Recruitment status	[ ] Prospectively registered
08/02/2010	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
25/02/2010	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
16/08/2011	Nutritional, Metabolic, Endocrine	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Nina Mikirova

Contact details
3100 North Hillside Avenue
Wichita
United States of America
67219

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
2009-02

Study information

Scientific Title

Effect of Stem-Kine Food Supplement on Circulating Stem Cells: an observational trial

Acronym
ESFSCSC

Study objectives
The food supplement Stem-Kine may cause a modulation of circulating stem cell numbers in healthy volunteers

Ethics approval required
Old ethics approval format

Ethics approval(s)
Institutional Review Board of The Center for Improvement of Human Health International, Wichita, Kansas, USA approved on the 29th of July 2009 (ref: 2009-02)

Study design
Observational

Primary study design
Observational

Secondary study design
Cohort study

Study setting(s)
Other

Study type(s)
Other

Participant information sheet
Not available in web format, please use contact below to request a patient information sheet.

Health condition(s) or problem(s) studied
Healthy Volunteers

Interventions
Ingestion of the commercially-available food supplement Stem-Kine:
Two 8 ml blood draws in heparinized Vacutainer tubes are collected by venipuncture before administration of Stem-Kine supplementation (day 0) and at days 1, 2, 7, and 14. Study participants are required to ingest two capsules of Stem-Kine (700mg/capsule) in the morning and two in the evening for 14 days.
Comparison is made pre- and post- treatment all recruited subjects.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Alteration in circulating hematopoietic and endothelial progenitor cells.
Blood samples taken pre-supplementation (day 0), and at days 1, 2, 7, and 14 are analyzed by flow cytometry and colony forming assays

Secondary outcome measures
Changes in overall health/mood, based on self reporting

Overall study start date
01/08/2009

Completion date
01/12/2009

Eligibility

Key inclusion criteria
1. Healthy adults, ages 20-72
2. Signed informed consent

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
18

Key exclusion criteria
1. Systemic immune-compromised state
2. Ongoing infection or disease conditions
3. Significant abnormalities in biochemistry or complete blood count panels

Date of first enrolment
01/08/2009

Date of final enrolment
01/12/2009

Locations

Countries of recruitment
United States of America

Study participating centre
3100 North Hillside Avenue
Wichita
United States of America
67219

Sponsor information

Organisation
Medistem Inc (USA)

Sponsor details
9255 Towne Centre Drive, Suite 450
San Diego
United States of America
92122

Sponsor type
Industry

ROR
https://ror.org/03andxb27

Funder(s)

Funder type
Charity

Funder Name
Allan P Markin (Canada) - individual funder

Funder Name
The Aidan Foundation (USA)

Funder Name
The Center For The Improvement Of Human Functioning International (USA)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration